News
2023.11.22
Dx&Vx announced on the 22nd that it will promote its own development through the introduction of Oxford Vacmedix therapeutic anticancer vaccine, OVM-200.
OVM-200 is about to start phase 1b after completing phase 1a clinical trials in the first half of this year. In phase 1a of clinical trials, satisfactory results were secured and a recent research paper was published in an online journal (Advanced Therapeutics). Phase 1b clinical trials are under discussion that Oxford Vacmedix will be held in the UK, and Dx&Vx will be held in Asia, including Korea and China.
This vaccine enters our body and removes cancer cells. Over time, even if new cancer cells are created, immune cells remember and eliminate cancer cells.
According to DX&VX, ROP (reconjugated redundant peptide) technology applied to OVM-200 significantly increases immunity and increases vaccine effectiveness. In addition, the fact that cancer targets Survivin and a large number of people with experience and know-how in the entire process from new drug development to commercialization are joined as differences.
OVM-200 is highly safe in that it is a peptide vaccine. In addition, the method of selecting and approaching one antigen peptide only works for limited HLA in Human Leukocyte Antigen (HLA), an identifier that helps the immune system differentiate itself from foreign substances, but the peptide complex is expected to increase treatment efficiency as it is likely to act on more diverse HLA (about 30 types).
Dx&Vx predicts that if data is gathered that OVM-200 helps the prognosis of chemotherapy patients and prevents recurrence, it will be possible to develop a vaccine for anticancer prevention.
A company official said, "We plan to complete technology transfer by the end of this year, conduct phase 1b and phase 2 clinical trials in major Asian countries, and release them through accelerated approval by 2027. If necessary, we are considering joint development or technology transfer with global big pharma."
Source：etoday